Table 1 Clinical characteristics before and after PSM according to radiotherapy or not.
From: Clinical features, treatment and prognosis analysis of distant metastatic esophageal cancer
Variables | Before matching | Pa value | After matching | P value | ||
|---|---|---|---|---|---|---|
Non-radiotherapy N = 981(%) | Radiotherapy N = 1087 (%) | Non- radiotherapy N = 771(%) | Radiotherapy N = 771(%) | |||
Sex | ||||||
Male | 811 (82.7%) | 907 (83.4%) | 0.684 | 644 (83.5%) | 644 (83.5%) | 1.000 |
Female | 170 (17.3%) | 180 (16.6%) | 127 (16.5%) | 127 (16.5%) | ||
Age | ||||||
< 65 years | 539 (54.9%) | 618 (56.9%) | 0.407 | 435 (56.4%) | 442 (57.3%) | 0.758 |
≥ 65 years | 442 (45.1%) | 469 (43.1%) | 336 (43.6%) | 329 (42.7%) | ||
Race | ||||||
White | 810 (82.6%) | 868 (79.9%) | 0.128 | 642 (83.3%) | 632 (82.0%) | 0.545 |
Unwhite | 171 (17.4%) | 219 (20.1%) | 129 (16.7%) | 139 (18.0%) | ||
Marriage | ||||||
Married | 458 (46.7%) | 440 (40.5%) | 0.005 | 429 (55.6%) | 432 (56.0%) | 0.918 |
Unmarried | 523 (53.3%) | 647 (59.5%) | 342 (44.4%) | 339 (44.0%) | ||
Chemotherapy | ||||||
None | 429 (43.7%) | 229 (21.1%) | < 0.001 | 252 (32.7%) | 226 (29.3%) | 0.169 |
Yes | 552 (56.3%) | 858 (78.9%) | 519 (67.3%) | 545 (70.7%) | ||
Primary site | ||||||
Cervical/Upper | 36 (3.7%) | 65 (6.0%) | < 0.001 | 31 (4.0%) | 30 (3.9%) | 0.667 |
Thoracic/middle | 170 (17.3%) | 207 (19.0%) | 142 (18.4%) | 137 (17.8%) | ||
Abdominal/lower | 699 (71.3%) | 768 (70.7%) | 558 (72.4%) | 561 (72.8%) | ||
Overlapping | 76 (7.7%) | 47 (4.3%) | 40 (5.2%) | 43 (5.6%) | ||
Histology | ||||||
Adenocarcinoma | 652 (66.5%) | 684 (62.9%) | 0.102 | 516 (66.9%) | 516 (66.9%) | 1.000 |
Non-adenocarcinoma | 329 (33.5%) | 403 (37.1%) | 255 (33.1%) | 255 (33.1%) | ||
Surgery | ||||||
None | 928 (94.6%) | 977 (89.9%) | < 0.001 | 726 (94.2%) | 733 (95.1%) | 0.498 |
Yes | 53 (5.4%) | 110 (10.1%) | 45 (5.8%) | 38 (4.9%) | ||
Grade | ||||||
I + II | 336 (34.3%) | 447 (41.1%) | 0.002 | 280 (36.3%) | 272 (35.3%) | 0.710 |
III + IV | 645(65.7%) | 640 (58.9%) | 491 (63.7%) | 499 (64.7%) | ||
T Stage | ||||||
T1 | 284(29.0%) | 244 (22.4%) | 0.950 | 217 (28.1%) | 197 (25.6%) | 0.817 |
T2 | 50 (5.1%) | 70 (6.4%) | 37 (4.8%) | 47 (6.1%) | ||
T3 | 208 (21.2%) | 361 (33.2%) | 176 (22.8%) | 214 (27.8%) | ||
T4 | 253 (25.8%) | 254 (23.4%) | 206 (26.7%) | 193 (25.0%) | ||
Tx | 186 (19.0%) | 158 (14.5%) | 135 (17.5%) | 120 (15.6%) | ||
N Stage | ||||||
N0 | 268 (27.3%) | 288 (26.5%) | 0.076 | 211 (27.4%) | 206 (26.7%) | 0.652 |
N1 | 600 (61.2%) | 731 (67.2%) | 489 (63.4%) | 509 (66.0%) | ||
Nx | 113 (11.5%) | 68 (6.3%) | 71 (9.2%) | 56 (7.3%) | ||
M Stage | ||||||
M1a | 44 (4.5%) | 150 (13.8%) | < 0.001 | 43 (5.6%) | 31 (4.0%) | 0.190 |
M1b | 937 (95.5%) | 937 (86.2%) | 728 (94.4%) | 740 (96.0%) | ||
Vital status | ||||||
Alive | 20 (2.0%) | 32 (2.9%) | 0.189 | 15 (1.9%) | 19 (2.5%) | 0.488 |
Death | 961 (98.0%) | 1055 (97.1%) | 756 (98.1%) | 752 (97.5%) | ||
